Thyroid Cancer Treatment (PDQ®)–Health Professional Version

SECTIONS

Changes to This Summary (04/12/2017)

The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.

General Information About Thyroid Cancer

Updated statistics with estimated new cases and deaths for 2017 (cited American Cancer Society as reference 2).

Treatment Option Overview for Thyroid Cancer

Revised Table 1 to add targeted therapy as an additional treatment option for locally advanced and metastatic medullary thyroid cancer (MTC).

Papillary and Follicular Thyroid Cancer

Added Lenvatinib as a new subsection under stage IV disease.

Added Lenvatinib as a new subsection under recurrent disease.

Medullary Thyroid Cancer

Added Cabozantinib as a new subsection.

This summary is written and maintained by the PDQ Adult Treatment Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ® - NCI's Comprehensive Cancer Database pages.

< Previous section
Anaplastic Thyroid Cancer

Next section >
About This PDQ Summary